Merck Sharp + Dohme Corp.

Guangdong Raynovent Biotech Co., Ltd.

Cgenetech (Suzhou, China) Co., Ltd.

Harbin Zhenbao Pharmaceutical Co., Ltd.

Novaonco Js Therapeutics Co., Ltd.

Other

Medshine Discovery Inc.

Yaopharma Co., Ltd.

Guangdong Zhongsheng Pharmaceutical Co., Ltd

Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory

Wuxi Life Fountain Biotech Co., Ltd

Chongqing Pharmaceutical Industrial Research Institute Co. Ltd.

Guangdong Xianqiang Pharmaceutical Co., Ltd

Cspc Zhongqi Pharmaceuticall Technology (Shijiazhuang) Co., Ltd.

Shenzhen Lingfang Biotech Co., Ltd.

Zhengxia Chen

Shuhui Chen

Meibi Dai

Jian Li

Xiaoxin Chen

Chaofeng Long

Zhuowei Liu

William K Hagmann

Bin Hu

Hubert B Josien

Guoping Hu

Purakkattle J Biju

Timothy Allen Blizzard

Mingxiang Cui

Ravi P Nargund

Qun Dang

Jie Li

Bing Li

Linus S Lin

Christopher W Plummer

Cheng Xie

Guibai Liang

Xing Liu

Tesfaye Biftu

Peng Li

Wei Wang

Barbara A Pio

Fei Sun

Cheng Zhu

Bowei Wang

Derun Li

Harry R Chobanian

Tao Feng

Timothy A Blizzard

Yang Zhang

Yikai Wang

Deheng Sun

Jian Zuo

Yuanfeng Xia

Wenju Li

Zhiqiang Liu

Jessica Frie

Zhen Gong

Anilkumar G Nair

Jikui Sun

Zhifei Fu

Jason W Szewczyk

Matthew John Clements

Dann Parker

Haizhong Tan

Jinglai Hao

Zhengwei Li

Candido Gude

Jian Wei Li

Haixia Zhao

Jiangpeng Liao

Yangyang Xu

Qiu Li

Yingxia Bao

Jiansong Wang

Zhibo Luo

Zhoufan Xie

Linlin Chen

Lili Tian

Zaihong Zhang

Ying Lv

Suqin Yang

Hongfei Cheng

Deyao Li

Rongxin Huang

Tesfaye Bifu

Jessica L Frie

The present invention relates to a PD-L1 immunomodulator, and specifically discloses a compound of formula (I) as a PD-L1 immunomodulator, a pharmaceutically acceptable salt or an isomer thereof.

Fluorovinylbenzamide compound as PD-L1 immunomodulator

FGFR and VEGFR dual inhibitors, specifically being a compound represented by formula (I) or a pharmaceutically acceptable salt.

Pyridine derivative as FGFR and VEGFR dual inhibitors

A fused ring compound as an FGFR and VEGFR dual inhibitor. Particularly, disclosed is a compound represented by formula (III) or a pharmaceutically acceptable salt thereof.

Fused ring compound as FGFR and VEGFR dual inhibitor

A series of pyrazolopymidine derivatives, and use thereof in the preparation of a medicament for treating disease associated with FGFR and c-Met. The pyrazolopymidine derivative is a compound represented by formula (I), a tautomer, or a pharmaceutically acceptable salt thereof.

Azaindole derivative and use thereof as FGFR and C-Met inhibitor

Disclosed is a series of pyrazolopyridine compounds, and application thereof in the preparation of RET kinase inhibitors for treatment. Specifically disclosed is the compound represented by formula (I), or a pharmaceutically acceptable salt thereof.

Pyrazolopyridine compound as RET inhibitor and application thereof

Disclosed is a PD-L1 inhibitor, and specifically disclosed is a compound of formula (I) as a PD-L1 immunomodulator, a pharmaceutically acceptable salt or an isomer thereof.

Vinylpyridine carboxamide compound as PD-L1 immunomodulator

A crystal form of an azaindole derivative and a preparation method thereof are disclosed.

Crystal form of azaindole derivative and use thereof

The present invention provides a salt form, a crystal form, and a preparation method of a compound as an FGFR4 inhibitor and medical uses thereof. 

Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof

Provided is a FGFR inhibitor, designating a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. Also provided is the application of a drug for treating solid tumors, such as FGFR related diseases. 

Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors

A quinoline derivative compound shown in formula (II), a pharmaceutically acceptable salt thereof, and an application of the same in preparing a drug for treating a disease related to a tyrosine kinase inhibitor. 

Quinoline derivative and use thereof as tyrosine kinase inhibitor

Disclosed in the present invention are a salt form and a crystal form serving as FGFR and VEGFR inhibitor compounds, a preparation method therefor, and medical uses thereof. 

Salt form and crystal form serving as FGFR and VEGFR inhibitor compounds, and preparation method therefor

Provided are a class of compounds as shown in formula (I) as FGFR4 inhibitors, and pharmaceutically acceptable salts thereof, preparation methods therefor and the use thereof in the preparation of drugs for treating FGFR4-related diseases. 

FGFR4 inhibitor and preparation method and use thereof

Disclosed are a crystal form and a salt form of and a preparation method for a tyrosine kinase inhibitor. 

Crystal form and salt form of and preparation method for tyrosine kinase inhibitor

The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same. The tyrosine kinase inhibitor of the present invention has the structures as shown in the following formula (I) or (II): 

Tyrosine kinase inhibitor and pharmaceutical composition comprising same

FGFR and VEGFR inhibitors are provided, and compounds represented by formula (1) or formula (II) as FGFR and VEGFR inhibitors, pharmaceutically acceptable salts or tautomers thereof are specifically disclosed.

Vinyl compounds as FGFR and VEGFR inhibitors

Growing community of inventors

Shanghai, China

Zhengxia Chen